Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120017/S039

Myocardial Pacing Lead

Medtronic, Inc. · Decision date Feb 20, 2026

FDA DECISIONP120017/S039

What did the FDA decide?

FDA records P120017/S039 as a supplement to PMA P120017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 20, 2026.

FDA approval order statement

an update to the part cleaning process at supplier
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 20, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P120017/S039
Regulatory pathway
PMA supplement
Product code
DTB
Decision code
OK30
Decision date
Feb 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: permanent pacemaker Electrode.

Product code
DTB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P120017/S039 received

    Application receipt date recorded by FDA.

  2. P120017/S039 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P120017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120017

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementApr 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records